Therapy News and Research

RSS

Money-saving tips for healthy, beautiful hair

These days, saving a little money here and there is all the rage. Even small changes - carpooling to work or making coffee at home - can really add up. But when it comes to cutting back on hair care, many people might be hesitant to make significant changes for fear that it could impact their looks and the health of their hair. That's where a dermatologist can help.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

New educational program for caregivers of patients with Lennox-Gastaut syndrome

Eisai Inc. introduced a new educational program today to help parents and caregivers of patients with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy in which patients have frequent seizures of multiple types.

11 Nov 2009

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

The National Institutes of Health (NIH) has awarded researchers at Rice University and the Texas Heart® Institute (THI) a $1 million Challenge Grant to refine cell-tracking nanotube technology that could make magnetic resonance imaging (MRI) up to 40 times more sensitive than existing MRIs and help guide adult stem cells within the human body to repair damaged hearts.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Hyperbaric oxygen therapy treatment ineffective for children with autism

Research conducted by the Center for Autism and Related Disorders, Inc. (CARD), shines new light on the effects of a popular form of hyperbaric oxygen therapy (HBOT) treatment for children with autism and related disorders. The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with Autism" study reveals that HBOT, consisting of 24% oxygen delivered at 1.3 atmospheres of pressure, does not have a significant effect on symptoms of autism.

10 Nov 2009

SAVI reaches a major milestone in breast brachytherapy

This month marks three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer – a major milestone in breast brachytherapy.

10 Nov 2009

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

Baxter International Inc. commends the Centers for Medicare and Medicaid Services (CMS) on announcing implementation plans for a new Medicare benefit that will provide Stage 4 chronic kidney disease patients with coverage for up to six sessions explaining their treatment options, such as transplantation, home peritoneal dialysis (PD), home hemodialysis (HHD) or clinic-based hemodialysis (HD).

From Baxter International Inc. 10 Nov 2009

Autism Spectrum Therapies approved to deliver ABA services to TRICARE military insurance beneficiaries

Autism Spectrum Therapies, an agency providing behavior therapy and other autism services in Southern California, has been approved to provide behavioral services for TRICARE military insurance beneficiaries. This designation makes AST eligible to deliver Applied Behavior Analysis (ABA) services to individuals with autism in military families in the San Diego area.

10 Nov 2009

Exposure to common infections may increase stroke risk

Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

Higher investment of physicians' time may be required to deliver high-quality care

Adult primary care visits have increased in quality, duration and frequency between 1997 and 2005, according to a report in the November 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Nov 2009

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.

10 Nov 2009

Therapy News and Research

Money-saving tips for healthy, beautiful hair

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Sprycel holds hope for treating Src dependent ovarian cancer

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Potential new drug for lung cancer eliminates tumors in mice

New educational program for caregivers of patients with Lennox-Gastaut syndrome

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

BioVex completes $70M financing to complete OncoVEX Phase III study

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Hyperbaric oxygen therapy treatment ineffective for children with autism

SAVI reaches a major milestone in breast brachytherapy

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

Autism Spectrum Therapies approved to deliver ABA services to TRICARE military insurance beneficiaries

Exposure to common infections may increase stroke risk

Study suggests a new improved treatment option for children with Hurler's syndrome

Higher investment of physicians' time may be required to deliver high-quality care

St. Jude collaborates with UF Proton Therapy Institute to commence proton therapy clinical study

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News